In vitro susceptibilities of clinical yeast isolates to a new echinocandin derivative, LY303366, and other antifungal agents

LY303366 is a new semisynthetic echinocandin derivative with potent, broad-spectrum fungicidal activity, We investigated the in vitro activity of LY303366, amphotericin B, flucytosine (5FC), fluconazole, and itraconazole against 435 clinical yeast isolates (413 Candida and 22 Saccharomyces cerevisiae isolates) obtained from over 30 different medical centers, MICs for all five antifungal agents were determined by the National Committee for Clinical Laboratory Standards method with RPMI 1640 test medium, LY303366 was also tested in antibiotic medium 3 as specified by the manufacturer, Overall, LY303366 was quite active against all of the yeast isolates when tested in RPMI 1640 (MIG at which 90% of the isolates are inhibited [MIG(90)], 1.0 mu g/ml) but appeared to be considerably more potent when tested in antibiotic medium 3 (MIC(90), 0.03 mu g/ml). When tested in antibiotic medium 3, LY303366 was 16- to >2,000-fold more active than itraconazole, fluconazole, amphotericin B, or 5FC against all species except Candida parapsilosis, When tested in RPMI 1640, LY303366 was comparable to amphotericin B and itraconazole and more active than fluconazole and 5FC, All of the isolates for which fluconazole and itraconazole had elevated MICs (greater than or equal to 128 and greater than or equal to 2.0 mu g/ml, respectively) were inhibited by less than or equal to 0.007 mu g of LY303366/ml when tested in antibiotic medium 3 and less than or equal to 0.5 mu g/ml when tested in RPMI 1640, Based on these studies, LY303366 has promising antifungal activity and warrants further in vitro and in vivo investigation.